A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

[JLS1]

Maybe a possibility if bone marrow failure is triggered by treatments vs cancer invading bone marrow?:

A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)

clinicaltrials.gov/ct2/show...

Brief Summary:

The goal of this clinical research study is to determine whether it is safe and practical to give CK0801 (a Cord blood-derived T-regulatory cell product) to patients with bone marrow failure syndrome. Researchers want to determine the highest possible dose that is safe to be given. Researchers also want to learn if CK0801 may improve the symptoms of bone marrow failure syndrome.

Patients enrolled in this study will all have been diagnosed with treatment refractory bone marrow failure syndrome (which includes aplastic anemia, myelodysplastic syndrome, or myelofibrosis). Participants eligible to participate in this study are unable or unwilling to be treated with standard therapy or have failed standard therapy.

Locations

United States, Texas

The University of Texas MD Anderson Cancer Center Recruiting

Houston, Texas, United States, 77030

Contact: Tapan M Kadia, MD 713-563-3534 [e-mail]

Principal Investigator: Tapan M Kadia, MD

[joekaty]

Thanks for sharing this. Interesting info and will keep this in mind!